Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites
11 déc. 2023 08h00 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements
09 nov. 2023 16h05 HE
|
Tarsus Pharmaceuticals, Inc
Launched XDEMVY® (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis Achieved $1.7 million in net product sales with more than 1,700 dispensed bottles Strengthened...
Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
01 nov. 2023 18h35 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis
06 sept. 2023 08h00 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus to Present at Upcoming Investor Conferences
30 août 2023 16h30 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
24 août 2023 09h00 HE
|
Tarsus Pharmaceuticals, Inc
Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out of every 12 adults. XDEMVY is indicated for all adult patients with Demodex blepharitis and is available...
Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements
10 août 2023 16h05 HE
|
Tarsus Pharmaceuticals, Inc
XDEMVY™ (lotilaner ophthalmic solution) 0.25% received FDA approval for the treatment for Demodex blepharitis On track to have XDEMVY and sales force in market by the end of August 2023 Completed...
Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock
01 août 2023 22h30 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new...
Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock
31 juil. 2023 16h29 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new...
FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis
25 juil. 2023 07h00 HE
|
Tarsus Pharmaceuticals, Inc
XDEMVY is the first and only approved therapeutic for Demodex blepharitis, a highly prevalent eyelid disease that impacts approximately 25 million eye care patients in the U.S. XDEMVY targets the...